 |
|
Upcoming Events featuring
National CooperativeRx
|
|
 |
National CooperativeRx is a not-for-profit coalition founded and owned by plan sponsors to achieve higher value prescription benefits through volume purchasing, clinical solutions, actionable data and unparalleled customer service. For your sales and marketing needs, please contact us at 866-679-9479, extension 223
|
|
|
2013 Enhanced Pricing Terms Thank you for being a member of National CooperativeRx.
As a member, you can rest easy, knowing that you have a full team of skilled professionals watching out for your best interest in the pharmacy benefits industry. We're always working on your behalf, and because of that, you can expect enhanced pricing terms for 2013. This is a result of previously negotiated pricing enhancements for year 3 of our current contract.
The new terms that will automatically take effect for all cooperative members in 2013 include an increase both in discounts and in minimum rebate guarantees. Just one more reason to look forward to the new year!!
In addition, as we have previously communicated, we are well into the RFP and marketplace assessment process for the next contract period beginning January 1, 2014. We sought competitive proposals from 10 separate PBMs, and are now evaluating the proposals from the 6 respondents. We on track to share the fruits of this critical due diligence responsibility at the beginning of February 2013. We anticipate this will be one of many exciting, value-based news to look forward to in the new year.
With Warm Regards,
Your PBM Cooperative
|
|
Health. An experimental insomnia drug, suvorexant, is showing promise. Developed by Merck Research Laboratories, it is currently being reviewed by the US FDA. 10% of the US suffer from chronic insomnia, and this drug will be another option for that population. (Norton, 11/28) Full story
|
|
Reuters. Can the party drug Ecstasy help veterans who suffer from post-tramatic stress disorder (PTSD)? Studies show that the drug can decrease fear and increase trust. (McLeod, 11/26) Full story
|
Bloomberg. US prices for brand-name drugs have risen 6 times faster than inflation, while generic drug prices have declined 21.9%. Cheaper, generic drugs now take up 80% of the prescription drug market. (McClatchy, 11/29) Full Story
|
The Huffington Post. Auris Medical needed to find patients to test a new hearing loss drug on. They put up posters telling partygoers who experienced hearing loss while attending New Year's Eve firecrackers where to go to join the trial. It worked, and they were able to prove that the compound AM-111 posed no safety risk. The drug is still in development, but some say it has potential to become a blockbuster. (Copley, Hirschler, 12/2) Full Story
|
Fox News. The FDA has reversed its stance on the recalled atorvastatin from Ranbaxy Pharmaceutical. The FDA is now encouraging people to continue to take their medication. The drug isn't of the quality that the FDA would prefer, but the glass particles are the size of a grain of sand and pose no threat. (Cohen, 11/30) Full Story
|
Reuters. Possession of marijuana, medical or recreational, is now legal in the state of Washington, and expected to become legal in the state of Colorado next month. Growing, selling or possessing marijuana remains a federal crime. (Myers, 12/6) Full Story
|
The Chicago Tribune. The Supreme Court will consider whether generic drug manufacturers can be subjected to personal injury lawsuits that allege flaws in the design of drugs. A response is expected by the end of June. (Baynes, Stempel, 11/30) Full Story
|
|
 |
|
